Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations

被引：3

作者：

Otto, Carolin ^{[4
,5
]}

Schwarz, Tatjana ^{[6
,7
]}

Jeworowski, Lara M. ^{[6
,7
]}

Schmidt, Marie L. ^{[6
,7
]}

Walper, Felix ^{[6
,7
]}

Pache, Florence ^{[4
,5
]}

Schindler, Patrick ^{[4
,5
]}

Niederschweiberer, Moritz ^{[4
,5
]}

Krumbholz, Andi ^{[8
,9
]}

Rose, Ruben

Drosten, Christian ^{[6
,7
]}

Ruprecht, Klemens ^{[1
,2
,4
,5
]}

Corman, Victor M. ^{[2
,3
]}

机构：

[1] Free Univ Berlin, Charite Univ Med Berlin, Dept Neurol, D-10117 Berlin, Germany

[2] Humboldt Univ, Charitepl 1, D-10117 Berlin, Germany

[3] Free Univ Berlin, Charite Univ Med Berlin, Inst Virol, Charitepl 1, D-10117 Berlin, Germany

[4] Free Univ Berlin, Charite Univ Med Berlin, Dept Neurol, Berlin, Germany

[5] Humboldt Univ, Berlin, Germany

[6] Free Univ Berlin, Charite Univ Med Berlin, Inst Virol, Berlin, Germany

[7] Humboldt Univ, Germany German Ctr Infect Res DZ, Berlin, Germany

[8] Christian Albrechts Univ Kiel, Inst Infect Med, Germany Lab, Kiel, Germany

[9] Univ Med Ctr Schleswig Holstein, Germany Lab, Kiel, Germany

来源：

MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷 / 07期

基金：

欧盟地平线“2020”;

关键词：

Multiple sclerosis; immunology; COVID; vaccine; disease-modifying therapies; SARS-CoV-2;

D O I：

10.1177/13524585231161253

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations. Results: Frequencies of aCD20pwMS with detectable SARS-CoV-2-S1-IgG increased moderately between two (31/61 (51%)), three (31/57 (54%)), and four (17/26 (65%)) vaccinations. However, among patients with detectable SARS-CoV-2-S1-IgG, frequencies of high avidity (6/31 (19%) vs 11/17 (65%)) and Omicron neutralizing antibodies (0/10 (0%) vs 6/10 (60%)) increased strongly between two and four vaccinations. SARS-CoV-2-specific T cells were detectable in >92% after two or more vaccinations Conclusion: Additional vaccinations qualitatively improve SARS-CoV-2 antibody responses.

引用

页码：884 / 888

页数：5

共 19 条

[1] Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study
Madelon, Natacha
Lauper, Kim
Breville, Gautier
Royo, Irene Sabater
Goldstein, Rachel
Andrey, Diego O.
Grifoni, Alba
Sette, Alessandro
Kaiser, Laurent
Siegrist, Claire-Anne
Finckh, Axel
Lalive, Patrice H.
Didierlaurent, Arnaud M.
Eberhardt, Christiane S.
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E1037 - E1045
[2] Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
Hammer, Helly
Hoepner, Robert
Friedli, Christoph
Leib, Stephen L.
Suter-Riniker, Franziska
Diem, Lara
Kamber, Nicole
Chan, Andrew
Salmen, Anke
Kamm, Christian P.
VACCINES, 2022, 10 (06)
[3] Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
Mazziotti, Valentina
Crescenzo, Francesco
Tamanti, Agnese
Dapor, Caterina
Ziccardi, Stefano
Guandalini, Maddalena
Colombi, Annalisa
Camera, Valentina
Peloso, Angela
Pezzini, Francesco
Turano, Ermanna
Marastoni, Damiano
Calabrese, Massimiliano
BIOMEDICINES, 2022, 10 (12)
[4] Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
Bajwa, Hamza Mahmood
Novak, Frederik
Nilsson, Anna Christine
Nielsen, Christian
Holm, Dorte K.
Ostergaard, Kamilla
Witt, Agnes Hauschultz
Byg, Keld-Erik
Johansen, Isik S.
Mittl, Kristen
Rowles, William
Zamvil, Scott S.
Bove, Riley
Sabatino, Joseph J.
Sejbaek, Tobias
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
[5] Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?
Avasarala, Jagannadha
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (12) : 3094 - 3096
[6] Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-a longitudinal cohort study
Novak, Frederik
Nilsson, Anna Christine
Christensen, Emil Birch
Stougaard, Caroline Louise
Barnkob, Mike Bogetofte
Holm, Dorte K.
Witt, Agnes Hauschultz
Byg, Keld-Erik
Johansen, Isik S.
Nielsen, Christian
Sejbaek, Tobias
FRONTIERS IN IMMUNOLOGY, 2024, 15
[7] Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets
Grothe, Christoph
Steffen, Falk
Bittner, Stefan
JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2021, 13
[8] Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies
Drulovic, Jelena
Ivanovic, Jovana
Martinovic, Vanja
Tamas, Olivera
Veselinovic, Nikola
Cujic, Danica
Gnjatovic, Marija
Mesaros, Sarlota
Pekmezovic, Tatjana
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 54
[9] Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Piquet, Amanda L.
Corboy, John R.
Vollmer, Timothy L.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
[10] SARS-CoV-2 Vaccination Responses in Anti-CD20-Treated Progressive Multiple Sclerosis Patients Show Immunosenescence in Antigen-Specific B and T Cells
De Biasi, Sara
Ciobanu, Alin Liviu
Santacroce, Elena
Lo Tartaro, Domenico
Degliesposti, Gianluca
D'Angerio, Miriam
Leccese, Maristella
Cardi, Martina
Trenti, Tommaso
Cuccorese, Michela
Gibellini, Lara
Ferraro, Diana
Cossarizza, Andrea
VACCINES, 2024, 12 (08)

← 1 2 →